




Bergen 10th February 2010 John Marshall

### Overview of Novartis's activity on Sealice





## Changing the 'mind set' regarding how we look for Sealice remedies.



#### **Second generation best in Class**

New class of active or technology?

Significant length of protection?

Ease of administration important?

#### **Medium term**

#### **Best in Class**

New Class of active?

Prolonged duration of protection?

More effective treatment?

Ease of administration important?

#### **Short term**

#### **Resistance breaker**

Class of active with knowledge?


No durational protection?

Does not need to be 'best' treatment?

< 100% efficacy acceptable?



### Latest from Novartis: HTS ongoing and automated





## Concluding remarks



- There is no 'Quick Fix' today
- We do have candidates for the future
- We are doing everything we can to reduce time to 'availability'

# Sealice solutions are top priority in Novartis Animal Health

## Thank you







Novartis in-house dedicated sealice facility: open 2008

